Free shipping on all orders over $ 500

Recaticimab

Cat. No. M25092

All AbMole products are for research use only, cannot be used for human consumption.

Recaticimab Structure
Synonym:

SHR-1209

Price and Availability

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.


Quality Control & Documentation
Biological Activity

Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia.

Chemical Information
CAS Number 2361290-85-7
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Mingtong Xu, et al. BMC Med. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study

Related PCSK9 Products
PCSK9-IN-13 

PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC50 of 537 nM.

PCSK9 ligand 1 

PCSK9 ligand 1 is a selective proprotein convertase substilisin-like/kexin type 9 (PCSK9) ligand.

AZD0780

AZD0780 (PCSK9-IN-12, EX-A6975) is an oral, potentially first-in-class small molecule inhibitor of PCSK9. AZD0780 (PCSK9-IN-12, EX-A6975) has bind affinity for PCSK9 with a Kd value of <200 nM. AZD0780 (PCSK9-IN-12, EX-A6975) can be used for the research of cholesterol metabolism.

NNC0385-0434

NNC0385-0434 is a peptide based on the epidermal growth-factor-like domain A of the human LDLR peptide. NNC0385-0434 competitively binds free PCSK9 and subsequently prevents PCSK9 binding to the LDLR. NNC0385-0434 is an orally active peptide small molecule PCSK9 inhibitor for atherosclerosis-related studies.

CiVi-008

CiVi-008 is an orally active PCSK9 antisense oligonucleotide (ASO) inhibitor for studies related to disorders of lipid metabolism.

  Catalog
Abmole Inhibitor Catalog




Keywords: Recaticimab, SHR-1209 supplier, PCSK9, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.